Fluzoparib Capsules

DRUG4 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Sun Yat-sen University, The First Affiliated Hospital of Xiamen University, Risen (Suzhou) Pharma Tech Co., Ltd.

Conditions

Advanced Solid TumorsFallopian-tube CancerHigh Grade Endometrioid Ovarian CancerHigh Grade Serous Adenocarcinoma of OvaryOvarian CancerPrimary Peritoneal Cancer

Phase 1

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

RecruitingNCT06208410

Risen (Suzhou) Pharma Tech Co., Ltd.Advanced Solid Tumors

Start: 2024-01-11End: 2027-02-26Target: 306Updated: 2025-07-25

Phase 2

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Not yet recruitingNCT06063070

Sun Yat-sen UniversityFallopian-tube Cancer, High Grade Endometrioid Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary +2

Start: 2023-10-18End: 2027-10-30Target: 44Updated: 2023-10-02

Phase 3

A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

CompletedNCT03863860

Jiangsu HengRui Medicine Co., Ltd.Ovarian Cancer

Start: 2019-04-30End: 2025-06-19Updated: 2025-07-03

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

Not yet recruitingNCT06188455

The First Affiliated Hospital of Xiamen UniversityOvarian Cancer

Start: 2024-12-01End: 2026-12-01Target: 37Updated: 2024-01-03